FindTrial
Sign In

Serum selenium and its therapeutic effects on serum biomarkers in hemodialysis patients

The study of effects serum selenium on serum biomarkers in hemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013081414333N2
Enrollment
100
Registered
2013-09-17
Start date
2013-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients. End-stage renal disease

Interventions

Intervention 1: daily prescription of selenium supplement for 3 months. Intervention 2: daily prescription of pacebo capsule containing starch for 3 months.
Treatment - Drugs
daily prescription of selenium supplement for 3 months
daily prescription of pacebo capsule containing starch for 3 months

Sponsors

Vice Chancellor for Research Affairs, Kermanshah University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: the patient's willingness to cooperate; at least 6 months passing after dialysis starting . Exclusion criteria: hepatitis; other infectious diseases; steroidal and non-steroidal anti-inflammatory drugs or vitamins E,C usage within two months before the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Selenium. Timepoint: day 0,90. Method of measurement: by cell counter.;Cholestrol. Timepoint: day 0 ,90. Method of measurement: by cell counter.;H.d.L. Timepoint: day 0,90. Method of measurement: by cell counter.;L.D.L. Timepoint: day 0,90. Method of measurement: by cell counter.;Serum. Timepoint: day 0,90. Method of measurement: by cell counter.;Triglycerides. Timepoint: day 0,90. Method of measurement: by cell counter.—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026